CTLA4 and cancer: Particularly, monoclonal antibodies targeting the immune checkpoints cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have shown dramatic efficacy and have been approved by the FDA for cancer treatment [1–4].